Oxford BioMedica could pocket $100m on Novartis CAR-T cell success – BioPharma-Reporter.com
|
Oxford BioMedica could pocket $100m on Novartis CAR–T cell success
BioPharma-Reporter.com The US approval of the first autologous chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel) has been heralded as a historic moment in cancer treatment, and at a price of $475,000 (€400,000) for a one-time infusion, is set to … |
LancasterOnline |
Penn Medicine & CHOP were instrumental in developing ‘breakthrough’ gene therapy
LancasterOnline The Food and Drug Administration has approved the first treatment that genetically engineers patients’ own blood cells into an army of assassins to seek and destroy childhood leukemia. Here’s a look at how the powerful CAR-T cell therapy works. (Aug. 30). FDA approves new gene therapy treatment for leukemia developed by Penn Medicine and CHOPFOX43.com |
LancasterOnline |
Penn Medicine & CHOP were instrumental in developing ‘breakthrough’ gene therapy
LancasterOnline The Food and Drug Administration has approved the first treatment that genetically engineers patients’ own blood cells into an army of assassins to seek and destroy childhood leukemia. Here’s a look at how the powerful CAR-T cell therapy works. (Aug. 30). FDA approves new gene therapy treatment for leukemia developed by Penn Medicine and CHOPFOX43.com |
|
‘Gentler’ CRISPR sheds light on autoimmune disease
FierceBiotech CRISPR is typically used to edit disease-causing gene mutations, but is increasingly being tapped for broader applications. The latest? Identifying sequences that activate genes, which could help unravel the causes of autoimmune disease. While CRISPR … |
|
‘Gentler’ CRISPR sheds light on autoimmune disease
FierceBiotech CRISPR is typically used to edit disease-causing gene mutations, but is increasingly being tapped for broader applications. The latest? Identifying sequences that activate genes, which could help unravel the causes of autoimmune disease. While CRISPR … |
|
Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol
Markets Insider The clinical trial adds an additional component to the pre-surgery radiation/chemotherapy regimen – immunotherapy. It is administered in the form of daily pills for two weeks prior to radiation and chemotherapy, and then during that treatment as well. |
|
Beta blockers capable of reducing stress signaling may enhance effectiveness of immunotherapy
News-Medical.net While the development of therapies designed to block “checkpoints” within the immune system has been one of the most exciting and noteworthy advances in cancer research in recent years, it’s also been one of the most puzzling, leaving researchers to … |
|
EBI Team Developing Genome Editing Resource for CRISPR Experimental Data
GenomeWeb NEW YORK (GenomeWeb) – Researchers at the European Molecular Biology Laboratory’s European Bioinformatics Institute in the UK are developing a new database to collect, curate, and convey data generated by CRISPR/Cas9 experiments. The team … |